Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60

Raymond James analyst Tiago Fauth initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $60.